Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30599144 | 1.00 | CYP1A2 (0.41) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL30886415 | 1.00 | CYP1A2 (0.41) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL25395550 | 1.00 | CYP1A2 (0.41) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| SCHEMBL812782 | 0.98 | CYP1A2 (0.42) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| SCHEMBL26252135 | 0.98 | CYP1A2 (0.42) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| SCHEMBL31415343 | 0.93 | MAPT (0.40) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| SCHEMBL31415373 | 0.93 | MAPT (0.40) | CYP1A2NPSR1MAPTALDH1A1TDP1 | |
| SCHEMBL31415451 | 0.84 | NPSR1 (0.35) | CYP1A2NPSR1MAPTTDP1ARG1 | |
| SCHEMBL31415504 | 0.84 | NPSR1 (0.35) | CYP1A2NPSR1MAPTTDP1ARG1 | |
| SCHEMBL31415546 | 0.84 | NPSR1 (0.35) | CYP1A2NPSR1MAPTTDP1ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695231-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216209-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-7718706-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER AKTIENGESELLSCHAFT (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | LIEB FOLKER | 2008-04-03 | — | — | US | disclosed |
| US-7288676-B2 | Arylphenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7105471-B2 | Arylphenyl-substituted cyclic ketoenols | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20060122061-A1 | Arylphenyl-substituted cyclic ketoenols | LIEB FOLKER | 2006-06-08 | — | — | US | disclosed |
| US-20040167031-A1 | Arylphenyl-substituted cyclic ketoenols | LIEB FOLKER (DE) | 2004-08-26 | — | — | US | disclosed |
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | LIEB FOLKER (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6451843-B1 | Arylphenyl-substituted cyclic keto enols | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122061-A1 | Arylphenyl-substituted cyclic ketoenols | KCNE1, KCNQ3, KCNQ2 | CA2 1017/4885CYP1A2 29/4885NPSR1 1001/4885 |
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | KCNE1, KCNQ3, SULT1E1 | CA2 1145/4885CYP1A2 30/4885NPSR1 581/4885 |
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | KCNE1, DDT, KCNQ3 | CA2 903/4885CYP1A2 26/4885NPSR1 1271/4885 |
| US-20040167031-A1 | Arylphenyl-substituted cyclic ketoenols | KCNE1, CYP21A2, KCNQ3 | CA2 929/4885CYP1A2 25/4885NPSR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.